Skip to main content

Advertisement

Table 2 Statistics for serum Trx1 levels of normal controls and various cancer patients

From: Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses

  Normal (N) Control Breast Cancer (BC) LC* (I-IV) CRC (I-III) KC (I/II)
  NF NM NFM I-III I II III L D
# of values 50 50 100 197 66 70 61 106 91 111 63 30
Minimum 14.99 15.61 14.99 26.19 26.19 28.51 28.45 26.19 29.35 13.22 14.77 28.51
25% Percentile 23.98 22.35 23.26 35.53 32.99 35.9 39.45 35.82 34.91 25.23 27.71 25.79
Median 28.5 26.22 27.64 38.98 36 38.97 43.98 39.03 38.98 31.89 31.09 30.96
75% Percentile 32.04 31.97 31.96 44.77 39.08 44.74 50.45 44.72 44.94 37.84 38.29 35.54
Maximum 42.78 42.22 42.78 60.01 48.07 53.37 60.01 56.64 60.01 50 55.02 46.11
Mean 28.62 27.24 27.93 40.12 35.93 40.1 44.67 40.03 40.22 31.71 32.92 31.12
Std. Deviation 6.054 6.155 6.113 6.816 4.346 6.15 6.882 6.793 6.878 8.254 7.864 7.541
Std. Error 0.8561 0.8705 0.6113 0.4856 0.5349 0.7351 0.8812 0.6598 0.721 0.7835 0.9908 1.377
Lower 95% CI 26.9 25.49 26.72 39.16 34.86 38.63 42.91 38.72 38.79 30.16 30.94 28.31
Upper 95% CI 30.34 28.99 29.14 41.08 36.99 41.57 46.43 41.34 41.65 33.26 34.9 33.94
  1. *Abbreviation used: F; Female, M; Male, BC; Breast Cancer, L; lobular carcinoma of breast cancer, D; ductal carcinoma of breast cancer, LC; lung cancer, CRC; colorectal cancer, KC; kidney cancer, CI; confidential interval.